All In MedTech

FDA Clearance Tracker · P040020-S087

AcrySof IQ PanOptix Trifocal Intraocular Lens and AcrySof IQ PanOptix Toric Trifocal Intraocular Lens

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 26, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 26, 2019

Approved

Time to decision

207 days

Received Jan 31, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P040020-S087
Device name
AcrySof IQ PanOptix Trifocal Intraocular Lens and AcrySof IQ PanOptix Toric Trifocal Intraocular Lens
Applicant location
Fort Worth, TX
Received
Jan 31, 2019
Decided
Aug 26, 2019
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P040020

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code MFK

FDA's approval statement

As written in FDA's record.

Approval for the AcrySof® IQ PanOptix® Trifocal Intraocular lens, which is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL.Approval for the AcrySof® IQ PanOptix® Toric Trifocal Intraocular lens, which is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia and the reduction of residual refractive astigmatism, in adult patients in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL.

Source documents

Other decisions for Alcon Research, Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

4 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.